AstraZeneca

AstraZeneca Plc Monitor

AstraZeneca Plc Annual Report 2018
CR Monitor Issue: 
2019/0612
Company covered: 
AstraZeneca Plc
Period End: 
31 December, 2018
Report issued on 13 June 2019 covered the following practice issues:
Pronouncements
Adoption of IFRS 9 Financial Instruments, IFRS 15 Revenue from Contracts with Customers and IFRIC 22 Foreign Currency Transactions and Advance Consideration with effect from 1 January 2018.
Pronouncements
Disclosure in respect of future impacts of adoption of IFRIC 23 Uncertainty over Income Tax Treatments and IFRS 16 Leases has been provided.
Pronouncements
Disclosure in respect of Amendments to IFRS 2 Share-based Payments.
Change
Assets held for sale are disclosed separately within the statement of financial position.
Change
The equalisation of Guaranteed Minimum Pensions for men and women results in the recognition of a past service cost.
Change
Disclosures made in respect of post balance sheet events.

Fair value measurement information under IFRS

IFRS 13 “Fair value measurement” sets out a single consistent framework for measuring fair value within IFRS financial statements and outlines a standardised set of disclosures in respect of fair value measurements. IFRS 13 has been mandatory now for some years, with application being required for annual reporting periods beginning on or after 1 January 2013. This report sets out the results of how requirements of the standard have been put into practice, both in terms of measurement and disclosure, in the consolidated financial statements of 139 large public limited companies with year ends between 31 March 2016 and 1 April 2017. It is not an exhaustive study of all aspects of IFRS 13 application and its conclusions are limited to our findings in respect of the areas analysed within the financial statements reviewed.

Disclosure of the impacts of IFRS 16 "Leases"

IFRS 16 “Leases” will fundamentally change accounting by lessees as it requires assets previously off balance sheet under operating lease arrangements to be brought on balance sheet as is currently the case for finance leased assets. As a result on application companies will recognise both additional assets and additional liabilities. Consequently there will also be knock on effects in the income statement as operating lease charges are replaced by a depreciation charge and a finance expense. This report analyses the financial statements of a range of companies to firstly establish whether there has been any early adoption and secondly to establish what companies are disclosing in respect of IFRS 16 and its future impacts.

AstraZeneca plc Monitor

AstraZeneca plc Annual Report 2015
CR Monitor Issue: 
2016/0911
Company covered: 
AstraZeneca plc
Period End: 
31 December, 2015
Report issued on 27 September 2016 covered the following practice issues:
Change
Redefinition of what is considered revenue with the reclassification of externalisation income from other operating income to revenue.

FRS 101 "Reduced disclosure framework"- A review of application in parent company accounts of IFRS groups

The preparation of parent company financial statements is something that all consolidated IFRS groups have to consider. In light of the great level of recent change in this area in the UK this represents a one-off report giving guidance on the preparation of parent company financial statements under FRS 101 "Reduced Disclosure Framework". It focuses on UK groups that prepare IFRS consolidated accounts.

The report sets out the key findings from our review of the first-time application of FRS 101 “Reduced Disclosure Framework” by a group of 29 parent companies that prepare consolidated financial statements under IFRS.  We consider a number of points including: how companies informed shareholders of the intention to implement FRS 101; the format of the primary financial statements; disclosure of the list of exemptions taken; the concept of equivalent disclosure in the consolidated financial statements; the length of company financial statements under FRS 101; and changes in accounting policy on adoption. 

Pensions - AstraZeneca plc

Period End: 
31 December, 2015
Period End Date: 
2015-12-31
Listing Status: 
FTSE 100, S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
KPMG

Pensions - AstraZeneca PLC

Period End: 
31 December, 2014
Period End Date: 
2014-12-31
Listing Status: 
FTSE 100, S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
KPMG

Pensions - AstraZeneca PLC

Period End: 
31 December, 2014
Period End Date: 
2014-12-31
Listing Status: 
FTSE 100, S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
KPMG

R&D tax and expenditure credits: an emerging issue under IFRS

This report addresses accounting for the new research and development (R&D) expenditure credit (RDEC) available from Her Majesty's Revenue and Customs (HMRC), the responsible tax authority in the United Kingdom, the previous UK scheme still in force for some companies and a similar scheme in Europe.

Capital management - AstraZeneca

Period End: 
31 December 2013
Period End Date: 
2013-12-31
Listing Status: 
FTSE 100, S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
KPMG